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Abstract: One of the strategies proposed for the chemoprevention of degenerative diseases and
cancer involves upregulation of antioxidant and free radical detoxification gene products by
increasing the intracellular concentration of the transcription factor nuclear factor erythroid
2-related factor 2 (Nrf2). This can be achieved by disrupting the interaction between Nrf2 and
Kelch-like ECH associated protein 1 (Keap1), a substrate adaptor protein for a Cul3-dependent E3
ubiquitin ligase complex. Here, we describe the development of a high-throughput fluorescence
(or F€orster) resonance energy transfer assay for the identification of inhibitors of the Keap1-Nrf2
protein–protein interaction (PPI). The basis of this assay is the binding of a YFP-conjugated Keap1
Kelch binding domain to a CFP-conjugated Nrf2-derived 16-mer peptide containing a highly con-
served “ETGE” motif. The competition aspect of the assay was validated using unlabeled Nrf2-
derived 7-mer and 16-mer peptides and has potential as a screening tool for small molecule inhibi-
tors of the PPI. We discuss the development of this assay in the context of other methods used to
evaluate this PPI.
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Introduction
The development of therapies for the chemopreven-
tion of cancer and chronic neurodegenerative condi-
tions is an important, but challenging objective.1,2 In
this respect, the regulation of cytoprotective
responses in cells upon exposure to stressors is
receiving growing interest as a therapeutic target.
Fundamental regulators in this process include the
substrate adaptor protein Kelch-like ECH associated
protein 1 (Keap1) and the transcription factor
nuclear factor erythroid related factor 2 (Nrf2).3
Nrf2 is able to upregulate the expression of numer-
ous genes involved in protecting cells against
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carcinogenesis upon exposure to free radicals, elec-
trophiles, or oxidative stress. Under basal condi-
tions, Keap1 represses Nrf2 by targeting the
transcription factor for ubiquitination and degrada-
tion by the proteasome. The Nrf2 Neh2 domain is
responsible for binding to the Keap1 Kelch domain
using both “low-affinity” DLG (residues 24–31) and
“high-affinity” ETGE (78–82) motifs.4–6 These motifs
interact with Keap1 mainly via salt bridges between
Glu and Asp residues in Nrf2 and Arg residues in
the Keap1 Kelch domain.7 Certain natural com-
pounds (e.g., sulforaphane, curcumin) that activate
Nrf2 are able to oxidize or covalently modify cyste-
ine residues in the N-terminal broad complex, tram-
track, and bric-a-brac domain or intervening regions
of Keap1. It is proposed that this causes a conforma-
tional change in the Keap1 dimer–Cul3 complex
that inhibits ubiquitination of Nrf2.8–10
An alternative strategy for upregulating Nrf2
involves disrupting the interaction between Keap1
and Nrf2 by direct competition at the protein–pro-
tein interface. Such an approach has potential
advantages including a reversible inhibition mode
and the possibility of increased target specificity. We
and others have described the development of pep-
tide inhibitors of the protein–protein interaction
(PPI).11,12 More recently, small molecule inhibitors of
the Keap1-Nrf2 interaction have been identified,
although currently these are significantly less potent
than the peptide inhibitors.13,14
In this study, we describe the development of a
homogeneous and high-throughput assay based on
fluorescence or F€orster resonance energy transfer
(FRET) observed upon interaction between the
Keap1 Kelch domain and a 16-mer Nrf2-derived pep-
tide containing a high-affinity ETGE motif. The
FRET technique is widely used and has the advant-
age of conjugating stable fluorophores to interacting
proteins, which makes the assay relatively durable.
The additional benefits of sensitivity and consistency
makes this steady-state FRET assay well suited for
high-throughput screening (HTS). The optimized
FRET assay has been applied to quantify the bind-
ing activity of a range of Nrf2-derived peptides
based on the high-affinity ETGE motif that serve as
lead compounds for the development of potential
inhibitors of the PPI. We discuss the relative merits
of this assay in relation to fluorescence polarization
(FP), surface plasmon resonance (SPR), and isother-
mal titration calorimetry (ITC) methods that have
been applied previously.11,15–17
Results
FRET optimization and validation
The principle of FRET is dependent on the overlap
of the donor fluorescence emission spectrum with
the acceptor excitation spectrum. In this case, the
donor fluorophore is CFP conjugated to an ETGE
motif-containing 16-mer Nrf2-derived peptide (CFP-
Nrf2) and the acceptor is YFP conjugated to the
human Keap1 Kelch domain (YFP-Kelch) [Fig. 1(a)].
When the two fusion proteins associate, the fluoro-
phores are brought into close proximity (<10 nm).
The crystal structure of the human Keap1 Kelch
domain and interacting 16-mer Nrf2 peptide sug-
gested that a fluorophore situated at either the C- or
N-terminus of the Nrf2 peptide would be in
Figure 1. (A) Schematic representation of the domains of the YFP-Kelch and CFP-Nrf2 constructs. (B) Molecular model of the
YFP-Kelch and CFP-Nrf2 FRET pair constructed from the human Keap1 Kelch domain (red) and the 16-mer Nrf2 peptide (pink)
complex (PDB ref: 2FLU) and the fluorophores YFP (yellow; PDB Ref: 1YFP) and CFP (cyan; PDB Ref: 2WSN). The separation
of the CFP and YFP chromophore residues in the complex was estimated using Chimera software20 to be 628 nm, a distance
suitable for FRET (i.e., <10 nm). FRET is observed as a decreased emission at 475 nm and an increased emission at 527 nm.
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relatively close proximity (within 6–8 nm) to either
the C-or N-terminus of the Kelch domain when the
two proteins interact.7 The N-terminus of both pro-
teins was selected for fluorophore conjugation to
minimize potential steric hindrance when the two
proteins associate. When the donor fluorophores are
excited at 435 nm, a proportion of the absorbed
energy is directly transferred to the acceptor. This
results in a decreased emission of the donor at 475
nm as well as an increase in acceptor emission at
527 nm [Fig. 1(b)].
FRET resulting from the interaction of Nrf2
with Keap1 was demonstrated by a titration experi-
ment in which emission spectra were recorded after
the addition of YFP-Kelch at a range of concentra-
tions to a fixed concentration of CFP-Nrf2 [Fig.
2(b)]. In a separate experiment, CFP-Nrf2 was
titrated with unconjugated YFP to account for non-
specific interactions [Fig. 2(a)]. Also, emission spec-
tra of the acceptor and donor fusion proteins were
recorded separately to control for direct excitation of
the fluorophores. As both fusion protein constructs
have a TEV recognition site between the fluorescent
tag and the protein, the FRET signal was further
validated by the addition of ProTEV protease to a
solution containing CFP-Nrf2 and YFP-Kelch, and
as expected, this resulted in a rapid decrease in
FRET (data not shown). The efficiency of FRET was
quantified by measuring the decrease in donor emis-
sion at 475 nm. An optimum FRET efficiency (FE)
was recorded with 0.11 mM CFP-Nrf2 and 0.28 mM
YFP-Kelch (FE  0.23). The FRET signal measured
immediately after mixing the reagents and over a
24-h period was found to be stable throughout (data
not shown).
In order to investigate factors modulating the
observed FE, the effect of salt concentration in the
buffer system was examined. X-ray crystallography
studies of the complex formed between the Keap1
Kelch domain and the ETGE-containing Nrf2 pep-
tide show that the interaction has a significant elec-
trostatic component.7 This implies that high salt
concentrations in the buffer may screen charge-
charge interactions between Glu/Asp residues in the
Nrf2 peptide and Arg residues in the Kelch binding
site. Indeed, increasing the salt concentration (up to
an additional 150 mM NaCl) in 20 mM Tris-HCl pH
7.4 buffer had a detrimental effect on the FE (100%
FE (0.23) at 0 mM NaCl decreased to 80% FE at
50 mM NaCl, 40% FE at 100 mM NaCl, and 0%
FE at 150 mM NaCl). Since DMSO is often used as
a co-solvent for small molecules and peptides, a
range of DMSO concentrations were tested in the
assay system. Concentrations  1% v/v were found
to have a negative impact on the fluorophore emis-
sion spectra (data not shown). This limited the use
of DMSO to a concentration of 0.1% v/v.
FRET assay in a multiwell plate format
Following optimization of the FRET system using
the fluorescence spectrometer, the assay was
adapted to a multiwell plate format. In this layout,
an optimum FE was determined by titrating a fixed
concentration of CFP-Nrf2 (CFP-WT) with variable
concentrations of YFP-Kelch. A protein ratio of 0.11
mM CFP-Nrf2 and 0.20 mM YFP-Kelch was found to
achieve 80% of the maximal FE and was used sub-
sequently in competition assays (Fig. 3). In order to
demonstrate the specificity of the PPI, biologically
relevant Nrf2-derived peptides that were known to
exhibit a low binding affinity for the Keap1 Kelch
domain were tested.17 These peptides incorporated
mutations in the DLG (residues 24–31) and ETGE
(residues 78–82) binding motifs that have been
observed in certain human cancers. ITC studies sug-
gested that mutations in the ETGE motif of Nrf2
such as E79Q, T80K, and E82D compromise the
association with the Keap1 Kelch domain in
Figure 2. Fluorescence emission spectra by direct titration of 0.11 mM CFP-Nrf2 with: (A) Unconjugated YFP or (B) YFP-Kelch
at 0.05, 0.07, 0.09, 0.11, 0.20, 0.30, 0.40, 0.50, 0.60, 0.70, and 0.80 mM (dotted lines). The solid line represents the donor alone
before titration.
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cancerous tissue and cell lines, resulting in constitu-
tive Nrf2 activation.17 CFP-peptide conjugates con-
taining these three Nrf2 mutations were expressed
and purified (CFP-E79Q, CFP-T80K, and CFP-
E82D). FRET experiments were performed in which a
fixed concentration of the CFP recombinant proteins
was directly titrated with YFP-Kelch at a range of
concentrations. All three mutant proteins showed a
diminished affinity for the Kelch domain compared to
the wild-type CFP-peptide conjugate (CFP-WT). In
contrast, the affinity of the interaction can be
improved by using a CFP-peptide conjugate with a
double mutation E78P/F83L (CFP-E78P/F83L) that
previously we have shown to increase binding affin-
ity.11 Titration experiments with this construct show
an improved interaction compared to the wild-type
sequence (KD 5 0.04 mM vs. 0.08 mM) (Table I).
Next, we applied the assay to identify and char-
acterize compounds that competitively inhibit the
Keap1–Nrf2 interaction. As FRET is a sensitive
measurement of the PPI, FE reduces when an inhib-
itor is added to the system. To verify this reduction
in FE, fluorescence emission spectra were recorded
in the absence and presence of 10 mM of an (unla-
beled) Nrf2-derived peptide inhibitor (Fig. 4). The
dose-dependence of the change in FE was used to
determine IC50 values and rank the inhibitors. The
Z0 value20,21 was 0.63 6 0.07, confirming the suit-
ability of this competition assay for HTS (see Sup-
porting Information).
Unlabeled versions of the Nrf2-derived 16mer
peptide sequences in Table I were used to further
validate the suitability of the FRET assay for quan-
tifying competitive inhibition of the Keap12Nrf2
interaction. The results indicate that, as observed in
the ITC experiments and our FRET studies using
CFP conjugates, the three negative control peptides
(E79Q, T80K, and E82D) were unable to perturb the
association between CFP-Nrf2 and YFP-Kelch (Fig.
5). Moreover, the Nrf2 wild-type (Nrf2-WT) and
E78P/F83L peptides caused a dose-dependent reduc-
tion in FE. The E78P/F83L peptide was a more
potent inhibitor of the PPI than Nrf2-WT (IC50: 0.08
mM vs. 0.11 mM), consistent with the observations in
Table I.
The standardized competition assay conditions
were used to screen a series of previously
described11 Nrf2-derived 7-mer peptides (Fig. 6). The
decrease in peptide length (7mer vs. 16mer) had a
significant effect on the binding affinity for Keap1.
Truncation of the 16mer Nrf2-WT peptide resulted
in peptide 1 with a 30-fold higher IC50 value (3.34
mM vs. 0.11 mM). However, activity was improved
after substitution of the N-terminal acetyl for a ste-
aroyl group in peptide 2 (0.45 mM vs. 3.34 mM). This
favorable effect on affinity warrants further explora-
tion. Peptides 3, 4, and 5 are proline-substituted
versions of peptide 1 and show increased binding
activity. This confirms our previous observations
that the glutamate residue that precedes the ETGE
motif is not essential for binding and that this posi-
tion benefits from conformational restriction. Finally,
peptide 6 is a scrambled version of peptide 2 and
showed decreased binding by 32-fold, which dem-
onstrates the importance of an intact ETGE motif
for interaction with the Keap1 Kelch domain in this
assay. Overall, there is a close match between the
IC50 values from the FRET assay and our previously
described FP assay (Table II).11,21
Discussion
Direct modulation of the Keap1–Nrf2 interaction is
an emerging strategy to stabilize Nrf2 and induce
cytoprotective gene expression. We have developed a
high throughput steady-state homogeneous FRET
assay that complements other assays applied to this
PPI. FRET was observed by conjugating a CFP fluo-
rophore to a 16-mer Nrf2-derived peptide and a YFP
fluorophore to the Keap1 Kelch domain, which forms
Table I. Dissociation Constants and Bmax Values for CFP-Peptide Conjugates
Protein Sequence KD 6 SE (mM) Bmax (mM)
CFP-WT CFP-AFFAQLQLDEETGEFL 0.08 6 0.02 0.28
CFP-E79Q CFP-AFFAQLQLDEQTGEFL >0.1 –
CFP-T80K CFP-AFFAQLQLDEEKGEFL >0.1 –
CFP-E82D CFP-AFFAQLQLDEETGDFL >0.1 –
CFP-E78P/F83L CFP-AFFAQLQLDPETGELL 0.04 6 0.01 0.22
Figure 3. FRET efficiency of 0.11 mM CFP- peptide conju-
gates (• CFP-WT, ! CFP-E79Q, D CFP-T80K,  CFP-
E82D, 8 CFP-E78P/F83L) as a function of YFP-Kelch protein
concentration (mM).
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a specific binding signal that was validated by com-
parison with the unconjugated YFP control fluores-
cence. The CFP and YFP fluorescent proteins form a
FRET pair with good spectral properties; addition-
ally, conjugation to the proteins of interest simplifies
the purification process of the fusion proteins,
improves protein stability and increases to the
robustness of the assay.22–24 The ability to determine
the absolute concentration of fluorophore conjugated
proteins using their UV absorption and molar extinc-
tion coefficient improves the accuracy of dissociation
constant measurements.25 For energy transfer to be
possible, there needs to be a degree of spectral over-
lap between the donor and acceptor fluorophores.
However, this spectral overlap can cause issues
known as crosstalk or bleed-through.26 Excitation
crosstalk occurs when the acceptor is excited with
light at the excitation wavelength of the donor. Simi-
larly, emission crosstalk arises from leakage of donor
emission into the detection channel for acceptor emis-
sion. Determining FRET by quantifying the increase
in YFP emission introduces the risk of including
some emission bleed-through. We chose to use the
decrease in donor emission as a direct measure of FE,
as there is a reduced risk of spectral bleed-through in
the CFP fluorescence emission channel.19
The FRET method is distinct from a number of
other techniques that have been applied to this
interaction. It has a higher sensitivity and through-
put than standard isothermal calorimetry and does
not require the sample immobilization and signifi-
cant method development that is needed for SPR.27–
30 FRET has similarities to FP methods that have
been applied successfully to this PPI by several
groups in that the assay is homogeneous and high
throughput. However, the FRET assay can be
applied using less sophisticated plate readers with
Figure 4. Fluorescence emission spectra of YFP-Kelch and CFP-Nrf2 in the absence (A) and presence (B) of 10 mM of an (unla-
beled) Nrf2-derived peptide inhibitor. Shown are the emission spectra of the FRET pair (solid line), donor alone (dotted line),
acceptor alone (long-dashed line), and the sum of acceptor and donor (short-dashed line).
Figure 5. Competitive inhibition of FRET efficiency by (unla-
beled) 16-mer peptides (• Nrf2-WT, 8 E78P/F83L, ! E79Q,
DT80K,  E82D) as a function of competitor peptide
concentration.
Figure 6. Competitive inhibition of FRET efficiency by (unla-
beled) 7-mer peptides (• Ac-DEETGEF-OH, 8 St-DEETGEF-
OH, ! Ac-DPETGEF-OH, D Ph-DPETGEL-OH,  St-
DPETGEL-OH, w St-DEGEETF-OH) as a function of competi-
tor peptide concentration.
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simpler optics.31,32 Both methods can be confounded
by fluorescence interference from inhibitors, so sec-
ondary confirmation of hits is required in the con-
text of HTS. A particular benefit of the FRET
methodology in this case is the improvement in the
stability of the Keap1 Kelch domain that results from
conjugation to YFP. The time stability of this assay
over FP approaches may be advantageous for HTS.16
Some cell-based methods for identifying Nrf2 activat-
ing agents can be carried out in a relatively high-
throughput manner (e.g., luciferase reporter33 and
enzyme induction assays)34. However, they do not
provide direct information on the mechanism by
which Nrf2 transcriptional activity is induced.
Recently, FRET techniques have been applied to the
Keap12Nrf2 interaction in single live cells using a
multiphoton fluorescence lifetime imaging microscopy
technique.35 This variation to the FRET methodology
offers valuable insights into the protein interaction
mechanisms in a cellular context; however, it is not
yet amenable to a compound screening approach.
In summary, the FRET assay described here is a
sensitive way to quantify protein–protein binding,
with good signal stability and durability. Competition
of (unlabeled) Nrf2-derived peptide inhibitors was suc-
cessfully studied by determining the restored CFP flu-
orescence emission. These results provide an insight
into peptide structure–activity relationships and com-
plement previous FP studies by our group. Our on-
going work is focused on the application of this assay
to the identification of small molecule inhibitors of the
Keap12Nrf2 interaction. The developed FRET assay
proves to be a valuable method for studying the
Keap12Nrf2 interaction and can aid in the identifica-
tion and design of effective chemopreventive agents.
Materials and Methods
Materials
Primers were purchased from Eurofins, ProTev protease
was supplied by Promega, and the 16-mer Nrf2-derived
peptides were obtained from Peptide Synthetics.
Methods
cDNA cloning, protein expression, and purifica-
tion. The cDNA encoding the human Keap1 Kelch
domain (residues 321 – 609) was amplified by PCR
with the following primers: 50-AAAAGGATCCGCGC
CCAAGGTGGGCCG-30 (forward) and 50AAAAGCG
GCCGCTTAGGTGACAGCCACGCCCAC-30 (reverse).
The amplified product was digested with BamH1
and Not1 (NEB) and ligated into a pET28c-eYFP-
TEV plasmid.18 The Nrf2 and Nrf2 mutant sequen-
ces (E78P/F83L, E79Q, T80K, and E82D) were cre-
ated by annealing a forward and reverse primer
(details on primers in Supporting Information). The
annealed products were digested with BamH1 and
Not1 and ligated into a pET28c-eCFP-TEV plas-
mid18 to generate the CFP-Nrf2 expression plas-
mids. All plasmid constructs were expressed in
Escherichia coli Rosetta 2 (DE3) (MerckMillipore). A
1-L bacterial culture grown at 37C was induced
with 1 mM IPTG and incubated for 16 h at 21C
when the cells reached the exponential growth
phase (OD600 nm 5 0.4–0.6). The His-tagged
recombinant proteins were purified by immobilized
metal affinity chromatography on a 5-mL His-Trap
column (GE Healthcare Life Sciences) (purification
details in Supporting Information). All YFP-Kelch
and CFP-Nrf2 or CFP-Nrf2 mutant protein concen-
trations were determined by UV/visible spectroscopy,
using wavelengths of 514 and 435 nm for eYFP and
eCFP, respectively, and the extinction coefficients
83,400 M21cm21 (eYFP) and 28,750 M21cm21
(eCFP). In the text, the terms eCFP and eYFP are
used synonymously with CFP and YFP for
simplicity.
Fluorescence spectra. All fluorescence spectra
were acquired using a single sample unit Perki-
nElmer LS 55 luminescence spectrometer (5-nm slit
width, 1-nm interval, 1-s integration) and an excita-
tion wavelength of 435 nm. Fluorescence emission
spectra were recorded from 400 to 600 nm. Samples
were measured in cuvettes (3.5 mL volume, 10-mm
path length, Sarstedt).
FRET titration. Titration experiments were per-
formed using either a PerkinElmer LS55 lumines-
cence spectrometer or a Pherastar BMG Labtech
microplate reader (excitation filter: 430 nm, dual
emission filters: 480 and 530 nm). YFP-Kelch or
unconjugated YFP and CFP-Nrf2 or CFP-Nrf2
mutant proteins were diluted as appropriate in 20
Table II. IC50 Values for Nrf2-Derived 7-mer Peptides for the Interaction Between CFP-Nrf2 and YFP-Kelch
Peptide Sequence FRET IC50 6 SE (mM) FP IC50 6 SE (mM)
14
1 Ac-DEETGEF-OH 3.34 6 0.44 5.39 6 0.58
2 St-DEETGEF-OH 0.45 6 0.05 0.18 6 0.04
3 Ac-DPETGEF-OH 0.33 6 0.03 0.25 6 0.04
4 Ph-DPETGEL-OH 0.26 6 0.03 0.16 6 0.02
5 St-DPETGEL-OH 0.12 6 0.01 0.02 6 0.003
6 St-DEGEETF-OH 14.5 6 1.60 11.8 6 2.67
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mM Tris-HCl pH 7.4 buffer containing, 0.5 mM
DTT, 0.1 mM EDTA, and 5% v/v glycerol. Final con-
centrations of 0.05–0.80 mM or 0.01–0.50 mM YFP-
Kelch or unconjugated YFP were added to a final
concentration of 0.11 mM CFP-Nrf2 or CFP-Nrf2
mutant proteins. Fluorescence emission spectra of
YFP-Kelch or unconjugated YFP and CFP-Nrf2 or
CFP-Nrf2 mutant protein samples were recorded
separately. Binding curves were fitted by nonlinear
regression using SigmaPlot software (ligand binding,
one site saturation) and Kd and Bmax values were
determined.
FRET competition assay. Competition assays
were performed using a Pherastar BMG Labtech
microplate reader. In this format, a concentration of
0.11 mM CFP-Nrf2 and 0.20 mM YFP-Kelch were
used. Assays were performed with increasing con-
centrations of peptide inhibitor (0.001–100 mM) at a
final volume of 100 mL and a final DMSO concentra-
tion of 0.1% v/v in untreated black 96-well microtiter
plates (Corning). All measurements were carried out
in triplicate. Plates were read directly after mixing
the components. FEs were calculated using:
FE512
Fda1inhibitor
Fd1vehicle
where da is the donor emission in the presence of
the acceptor and d is the donor emission in the
absence of the acceptor19 and vehicle is 0.1% DMSO.
Percentage inhibition was determined using the cal-
culated FEs. Inhibition curves were fitted to a
standard four-parameter logistic function using Sig-
maPlot and IC50 values were determined.
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